Charenton-le-Pont, France (May 02, 2024) – EssilorLuxottica continues its long-standing partnership established more than a decade ago with the European Academy of Optometry and Optics (EAOO), by participating in its 15th annual conference on May 10-12, 2024, in Helsinki, Finland. The Company’s expertise in myopia management and advances in clinical refraction will take centre stage this year.

The latest evidence around myopia management is becoming increasingly important to help eyecare professionals understand the innovations available to better support their patients. As a global leader, EssilorLuxottica is committed to sharing recent research findings and myopia management solutions during a satellite symposium titled “Latest research evidence on Essilor Stellest lenses*” on May 11, 11.30-12.30 CET.

In this session, Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica and Gabi Steenbekkers, Medical Advisor, Myopia at EssilorLuxottica, will share the five-year clinical study results of the Essilor Stellest lens and other latest research evidence. The five-year findings show that Essilor Stellest lenses saved one and three-quarter dioptres of myopia over five years **1, demonstrating their long-term efficacy in slowing down myopia progression in children in the fifth year.

EssilorLuxottica is also committed to providing comprehensive and innovative technology with which practitioners can offer an immersive and personalized experience for their patients, with the aim to offer best vision correction. To this end, the Company will also host:

An exclusive workshop titled “Essilor Instruments Vision Lab - Hands on refraction” by Yaiza Garcia- Sanchez, Global Medical Advisor, and Paul Joret, Refraction Products Manager at EssilorLuxottica, on May 10, 11.00-12.00 CET.
A rapid-fire talk by Yaiza Garcia-Sanchez on May 11, 9.00 CET titled “Validation study of the Vision- STM 700: Comparing smart and standard refraction methods to gold standard”.
A lecture by Paul Joret on May 11, 14.00-14.30 CET, titled “Advancing clinical refraction: Assessing the efficacy of smart automated refraction programs”.

The theme of the conference this year is, "Advancing Optometry and Optics through Technology and Shared Care”. In addition to joining EssilorLuxottica’s sponsored sessions and workshops, attendees are welcome to stop by the Company’s booth where they can discover and experience the latest innovations in myopia, presbyopia as well as instruments, and how they are shaping the future of vision care. More information on the program can be found here.

“We look forward to participating in EAOO’s annual conference as a diamond sponsor this year. It’s a privilege to share our new evidence-based data and insights, such as the promising five-year results of the Essilor Stellest lenses, and to dialogue with our peers on research findings and solutions that will benefit patients. Together with EAOO, we look forward to sharing latest insights on myopia and refraction with researchers and eyecare professionals who will attend this conference,” said Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica.

Liliana Stankova, FMEAOO and FEAOO Founder and Fellow, President of the European Academy of Optometry and Optics, expressed her enthusiasm about the collaboration with EssilorLuxottica for the upcoming annual meeting in Helsinki in 2024. "This partnership is instrumental in elevating standards and advancing education in optometry and optics to cater to the diverse vision needs across Europe. Such impactful events require strong sponsorship, and we are deeply grateful for the generous support from EssilorLuxottica, our Diamond Sponsor, who has been a consistent supporter of the EAOO since its inception."

Panu Tast, CEO, Finnish Association of Vision and Eyecare said, “It's great to welcome industry leaders to Finland and finally be able to host the EAOO conference live in Helsinki. EssilorLuxottica's support is a great endorsement to the industry of their commitment to the development of the industry in Europe and emerging markets. In Finland, we are also delighted with the Group's contribution to industry legislation and the extension of optometrists' rights.”

Footnote

_{*Essilor Stellest lenses are not currently FDA approved and are not commercially available for sale in all countries, including the U.S.}

_{**Compared to the 60-month progression of the Virtual Control Group (predicted average annual decrease in SER by 9.7%, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811). 1. Li X, Huang Y, Liu C, Yin Z, Cui Z, Lim EW, Drobe B, Chen H, Bao J. Myopia control efficacy of Spectacle Lenses with Highly Aspherical Lenslets: results of a 5-year follow-up study. ARVO Annual Meeting, Seattle. 2024. Available at: https://eppro02.ativ.me/web/page.php?nav=false&page=IntHtml&project=ARVO24&id=4045389&external=true Last accessed 17 April 2024}

DOWNLOAD THE PRESS RELEASE

Back To List

EssilorLuxottica to present new insights on myopia management and advances in clinical refraction at EAOO 2024 in Helsinki